DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for DXCM, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dexcom Inc ranked in the 32th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 47%. As for the metrics that stood out in our discounted cash flow analysis of Dexcom Inc, consider:
The compound growth rate in the free cash flow of Dexcom Inc over the past 5.48 years is 0.77%; that's better than 84.57% of cash flow producing equities in the Healthcare sector, where it is classified.
97% of the company's capital comes from equity, which is greater than 89.85% of stocks in our cash flow based forecasting set.
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 10.11% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Dexcom Inc? See XRAY, CAH, BIO, JNJ, and PDEX.
Dexcom (NASDAQ: DXCM) went public on April 14, 2005. At that price, an investment of $1,000 would have gotten you 82 shares. It consisted of a tiny device inserted under the skin of a diabetes patient.
DexCom (DXCM) has issued a notice of redemption to holders of its outstanding 0.75% senior convertible notes due 2022. It will redeem the notes at a cash price of 100% of the principal amount plus accrued and unpaid interest.Prior to the redemption date, holders may convert into DexCom common stock...